Back to news

Insight Molecular Diagnostics Announces Proposed Public Offering

Globe Newswire•16/11/2026•16:10 ET
0

Key Highlights

  • ➤Insight Molecular Diagnostics (IMDX) commenced an underwritten public offering of common stock.
  • ➤Offering may include pre-funded warrants and a 30-day option for 15% additional shares.
  • ➤Proceeds are intended for working capital, corporate purposes, and transplantation research and development.
  • ➤Lake Street Capital Markets is acting as sole managing underwriter.

NASHVILLE, Tenn., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) (“iMDx,” “we,” “us,” “our,” or the “Company”) today announced that it has commenced an underwritten public offering of shares of its common stock, or, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. In addition, the Company intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the total number of shares of common stock offered in the public offering (including shares issuable upon exercise of the pre-funded warrants). The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the offering.

The Company intends to use the net proceeds from the offering for working capital and general corporate purposes, including but not limited to research and development in the transplantation category.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in